CNTA Centessa Pharmaceuticals
- 8.920
- -0.010-0.11%
Centessa Pharmaceuticals News
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively traded Invesco QQQ Trust (QQQ) was 0.6% higher in Wednesday's premarket activity, as earnings continue t
Express News | Reported Earlier, Centessa Pharmaceuticals Prices $100M Public Offering Of 10,810,810 American Depositary Shares At $9.25/ADS
Centessa Pharmaceuticals Eyes $100 Million in ADS Offering
Centessa Pharmaceuticals (CNTA) said Tuesday it is seeking to raise $100 million from an underwritten public offering of American Depositary Shares, each representing one ordinary share. The proposed
Express News | Announces $100M Proposed Public Offering Of American Depositary Shares
Press Release: Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA
Centessa Pharmaceuticals Advances Narcolepsy Drug Trials
Express News | The FDA Has Cleared Centessa Pharmaceuticals' Investigational New Drug Application To Initiate A Phase 1 First-in-human, Clinical Trial Of ORX750 For Narcolepsy
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
BOSTON and LONDON, April 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for
Buy Rating Affirmed for Centessa Pharmaceuticals Amid Promising ORX750 Prospects and Favorable Trial Results
Analysts' Top Healthcare Picks: AstraZeneca (AZN), Centessa Pharmaceuticals (CNTA)
Express News | BMO Capital Maintains Outperform on Centessa Pharmaceuticals, Maintains $15 Price Target
Centessa Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 36.49% BMO Capital $15 → $15 Maintains Outperform 11/15/2023 0.09% Jefferies $4 → $11 Upgrades
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Centessa Pharmaceuticals (CNTA)
Centessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 Results
Centessa Pharmaceuticals Q4 EPS $(0.38) Beats $(0.48) Estimate
Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.48) by 20.83 percent. This is a 15.56 percent increase over losse
Centessa Pharmaceuticals 4Q Loss/Shr 38c >CNTA
Centessa Pharmaceuticals 4Q Loss/Shr 38c >CNTA
Press Release: Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 -- Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 stu
Centessa Pharmaceuticals PLC Chief People Officer Sells Company Shares
Centessa Pharmaceuticals(CNTA.US) Officer Sells US$607.96K in Common Stocks
$Centessa Pharmaceuticals(CNTA.US)$ Officer Anderson Karen M. sold 51,160 shares of Common Stocks on Mar 25, 2024 at an average price of $11.8835 for a total value of $607.96K.Source: Announcement Wha
Centessa Pharmaceuticals Insider Sold Shares Worth $607,960, According to a Recent SEC Filing
Karen M. Anderson, Chief People Officer, on March 25, 2024, sold 51,160 shares in Centessa Pharmaceuticals (CNTA) for $607,960. Following the Form 4 filing with the SEC, Anderson has control over a to
Analysis
Price Target
No Data
